McClellan Leads the Way to New Postmarketing World
This article was originally published in RPM Report
Midway through the 2007 Congressional debate over new drug safety controls, Mark McClellan, MD, is emerging as a figure with the credentials, credibility and fund-raising capability to make the establishment of a public-private partnership for post-marketing surveillance a reality. Big Pharma better hope that McClellan is ultimately successful. If ever there was a time when a new, authoritative voice was needed to provide clarity to postmarketing safety issues, it is now.
You may also be interested in...
The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.
The Reagan-Udall Foundation is the one piece of the FDA drug safety law enacted in 2007 that both FDA and industry are excited about. Congressional appropriators, however, have serious concerns. The stakes are higher than they seem: in the short run, the Critical Path and active surveillance systems may depend on the foundation. In the long run, the question is whether industry has any say in the evolution of regulation.
The world of post-approval research is going to get more public, more crowded, and more dangerous to pharma. Post-marketing surveillance, transparent clinical trial results and mandated post-approval studies mean the traditional world of marketing-oriented Phase IV is about to change dramatically.